&lt;span class="caption"&gt;ORIGINAL ARTICLE:&lt;/span&gt;
Renal Outcome in Equipotent Antihypertensive Treatment with Telmisartan, Ramipril and in Combination in SHR-SP Rats

Schmerbach, Kristin; Kalk, Philipp; Wengenmayer, Christina; Lucht, Kristin; Unger, Thomas; Hocher, Berthold; Thoene-Reineke, Christa

doi:10.7754/clin.lab.2011.110622

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combination therapy was also associated with a significant decrease in proteinuria, at least in the short term (MacKinnon et al 2006). However, Schmerbach et al (2012) observed the effect of ACEI/ARB combination therapy in spontaneously hypertensive stroke-prone rats on a salt-rich diet. Renal glomerulosclerosis and interstitial fibrosis were decreased by monotherapy (telmisartan or ramipril), whereas combination treatment (telmisartan and ramipril) failed to have a significant effect.…”

Section: Acei + Arb Combinationmentioning

confidence: 99%

Antifibrotic Roles of RAAS Blockers: Update

Zhang

Chen

2019

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

The rennin-angiotensin-aldosterone system (RAAS) has been well documented in regulating blood pressure, fluid volume, and sodium balance. Overactivity of RAAS promotes both systemic and regional glomerular capillary hypertension, which could induce hemodynamic injury to the glomerulus, leading to kidney damage and renal fibrosis via profibrotic and proinflammatory pathway. Therefore, the use of RAAS inhibitors (i.e., ACEIs, ARBs, and MRAs) as the optional therapy has been demonstrated to prevent proteinuria, and kidney fibrosis and slow the decline of renal function effectively in the process of kidney disease during the last few decades. Recently, several new components of the RAAS have been discovered, including ACE2 and the corresponding ACE2/Ang (1-7)/Mas axis, which are also present in the kidney. Besides the classic RAAS inhibitors target the angiotensin-AT1-aldosterone axis, with the expanding knowledge about RAAS, a number of potential therapeutic targets in this system is emerging. Newer agents that are more specific are being developed. The present chapter outlines the insights of the RAAS agents (classic RAAS antagonists/the new RAAS drugs), and discusses its clinical application in the combat of renal fibrosis.

show abstract

Section: Acei + Arb Combinationmentioning

confidence: 99%

Antifibrotic Roles of RAAS Blockers: Update

Zhang

Chen

2019

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

show abstract

Should ACE inhibitors and ARBs be used in combination in children?

Stotter

Ferguson

2018

Pediatr Nephrol

View full text Add to dashboard Cite

The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in a host of renal and cardiovascular functions. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), drugs that disrupt RAAS function, are effective in treating hypertension and offer other renoprotective effects independent of blood pressure (BP) reduction. As our understanding of RAAS physiology and the feedback mechanisms of ACE inhibition and angiotensin receptor blockade have improved, questions have been raised as to whether combination ACEI/ARB therapy is warranted in certain patients with incomplete angiotensin blockade on one agent. In this review, we discuss the rationale for combination ACEI/ARB therapy and summarize the results of key adult studies and the limited pediatric literature that have investigated this therapeutic approach. We additionally review novel therapies that have been developed over the past decade as alternative approaches to combination ACEI/ARB therapy, or that may be potentially used in combination with ACEIs or ARBs, in which further adult and pediatric studies are needed.

show abstract

<span class="caption">ORIGINAL ARTICLE:</span> Renal Outcome in Equipotent Antihypertensive Treatment with Telmisartan, Ramipril and in Combination in SHR-SP Rats

Cited by 2 publications

References 0 publications

Antifibrotic Roles of RAAS Blockers: Update

Antifibrotic Roles of RAAS Blockers: Update

Should ACE inhibitors and ARBs be used in combination in children?

Contact Info

Product

Resources

About